ALKERMES | ALKS - Operating Expenses



ALKERMES reported $297.68M in Operating Expenses for its fiscal quarter ending in June of 2025.


Operating Expenses Change Date
AbbVie USD 9.71B 96M Jun/2025
Acadia Pharmaceuticals USD 232.19M 7.16M Jun/2025
ALKERMES USD 297.68M 4.96M Jun/2025
Amgen USD 6.52B 337M Jun/2025
Biogen USD 1.79B 326.1M Jun/2025
BioMarin Pharmaceutical USD 548.52M 27.27M Jun/2025
Bristol-Myers Squibb USD 8.5B 265M Jun/2025
Eli Lilly USD 8.54B 1.22B Jun/2025
Gilead Sciences USD 4.35B 80M Jun/2025
Ionis Pharmaceuticals USD 312.21M 34.21M Jun/2025
J&J USD 16.8B 8.54B Jun/2025
Malin Corporation EUR 1.1M 400K Dec/2024
Merck USD 9.44B 217M Jun/2025
Neurocrine Biosciences USD 541.9M 7M Jun/2025
Otsuka Holdings JPY 490.92B 32.5B Jun/2025
Pfizer USD 11.62B 1.58B Jun/2025
Regeneron Pharmaceuticals USD 2.6B 159.1M Jun/2025
Vertex Pharmaceuticals USD 1.81B 71.4M Jun/2025